Scholarlink

Introduction <p>Diabetes mellitus (DM) is a chronic metabolic disorder marked by persistent hyperglycemia. While HbA1c has traditionally been used to assess glycemic control, growing evidence highlights glycemic variability (GV) and Time in Range (TIR) as more precise indicators of glucose fluctuations, which are linked to diabetic complications, especially chronic kidney disease (CKD). Emerging combination therapies targeting different pathophysiologic mechanisms of type 2 diabetes mellitus (T2DM), such as SGLT2 inhibitors and DPP-4 inhibitors, offer promise in reducing GV.</p> Objective <p>To compare the efficacy of three commonly prescribed fixed-dose combination (FDC) therapies—Teneligliptin + Dapagliflozin (Arm-A), Sitagliptin + Dapagliflozin (Arm-B), and Linagliptin + Empagliflozin (Arm-C)—in improving glycemic control and renal parameters in Indian T2DM patients using continuous glucose monitoring (CGM).</p> Method <p>This prospective, comparative study enrolled 90 patients (30 in each arm). CGM was used to evaluate glycemic parameters including TIR, TAR, TBR, MAGE, LAGE, MPPGE, HbA1c, FPG, PPG, and renal function indicators (eGFR, serum creatinine, BUN) at baseline and study conclusion.</p> Results <p>All arms demonstrated significant improvements in TIR, MAGE, LAGE, HbA1c, FPG, and PPG (p&lt;0.001). Arm-A showed a significantly superior reduction in TAR and MPPGE compared to Arm-B (p=0.029 and p=0.040, respectively) and also outperformed Arm-B in reducing FPG (p=0.042). Renal function improved comparably across arms, with a significant decline in serum creatinine noted in Arm-A.</p> Conclusion <p>All three FDC therapies significantly improved glycemia, with the Teneligliptin + Dapagliflozin combination offering slightly superior efficacy in reducing TAR, MPPGE, and FPG. These findings support its clinical utility in reducing glycemic variability in patients with T2DM in India. Although favorable trends were observed in renal parameters, the study duration was too short to draw definitive conclusions regarding renal safety. As such, references to renal outcomes should be interpreted with caution, and further long-term studies are warranted to validate these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Triple arm, prospective, real-world study comparing the efficacy of FDC teneligliptin + dapagliflozin to FDC sitagliptin + dapagliflozin, and FDC linagliptin + empagliflozin in Indian type 2 diabetes mellitus patients using CGM device: the Amplify-TIR study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Suhas Erande,
  • Mayur Agrawal,
  • Sanjeev Gulati,
  • Namdev Jagtap,
  • N. S. Praveen Kumar,
  • Vinod Kumar Kapoor,
  • Sumit Bhushan,
  • Rujuta Gadkari,
  • Mayur Jadhav,
  • Sanjay Choudhari,
  • Saiprasad Patil,
  • Hanmant Barkate

摘要

Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder marked by persistent hyperglycemia. While HbA1c has traditionally been used to assess glycemic control, growing evidence highlights glycemic variability (GV) and Time in Range (TIR) as more precise indicators of glucose fluctuations, which are linked to diabetic complications, especially chronic kidney disease (CKD). Emerging combination therapies targeting different pathophysiologic mechanisms of type 2 diabetes mellitus (T2DM), such as SGLT2 inhibitors and DPP-4 inhibitors, offer promise in reducing GV.

Objective

To compare the efficacy of three commonly prescribed fixed-dose combination (FDC) therapies—Teneligliptin + Dapagliflozin (Arm-A), Sitagliptin + Dapagliflozin (Arm-B), and Linagliptin + Empagliflozin (Arm-C)—in improving glycemic control and renal parameters in Indian T2DM patients using continuous glucose monitoring (CGM).

Method

This prospective, comparative study enrolled 90 patients (30 in each arm). CGM was used to evaluate glycemic parameters including TIR, TAR, TBR, MAGE, LAGE, MPPGE, HbA1c, FPG, PPG, and renal function indicators (eGFR, serum creatinine, BUN) at baseline and study conclusion.

Results

All arms demonstrated significant improvements in TIR, MAGE, LAGE, HbA1c, FPG, and PPG (p<0.001). Arm-A showed a significantly superior reduction in TAR and MPPGE compared to Arm-B (p=0.029 and p=0.040, respectively) and also outperformed Arm-B in reducing FPG (p=0.042). Renal function improved comparably across arms, with a significant decline in serum creatinine noted in Arm-A.

Conclusion

All three FDC therapies significantly improved glycemia, with the Teneligliptin + Dapagliflozin combination offering slightly superior efficacy in reducing TAR, MPPGE, and FPG. These findings support its clinical utility in reducing glycemic variability in patients with T2DM in India. Although favorable trends were observed in renal parameters, the study duration was too short to draw definitive conclusions regarding renal safety. As such, references to renal outcomes should be interpreted with caution, and further long-term studies are warranted to validate these findings.